Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab + Doxorubicin + Ifosfamide in Advanced STS
NCT03283696Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of olaratumab in soft tissue sarcoma (STS), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Olaratumab Dose Limiting Toxicities. Started Oct 2017; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03283696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283696.